CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues
Revenues	$ 2,136	$ 2,219	$ 6,259	$ 6,561
Expenses
Selling, general and administrative	614	623	1,847	1,943
Research and development	107	81	293	271
Amortization of intangible assets	658	657	2,142	1,915
Goodwill impairments	0	312	2,213	312
Asset impairments	89	406	434	629
Restructuring and integration costs	3	6	16	42
Acquired in-process research and development costs	0	0	1	5
Acquisition-related contingent consideration	(19)	(238)	(23)	(297)
Other income, net	(15)	(325)	(4)	(584)
Total expenses	2,019	2,181	8,668	6,137
Operating income (loss)	117	38	(2,409)	424
Interest income	3	3	9	9
Interest expense	(420)	(459)	(1,271)	(1,392)
Loss on extinguishment of debt	0	(1)	(75)	(65)
Foreign exchange and other	0	19	18	87
Loss before (provision for) benefit from income taxes	(300)	(400)	(3,728)	(937)
(Provision for) benefit from income taxes	(51)	1,700	(74)	2,829
Net (loss) income	(351)	1,300	(3,802)	1,892
Net loss (income) attributable to noncontrolling interest	1	1	(2)	(1)
Net (loss) income attributable to Bausch Health Companies Inc.	$ (350)	$ 1,301	$ (3,804)	$ 1,891
(Loss) earnings per share attributable to Bausch Health Companies Inc.:
Basic (in usd per share)	$ (1.00)	$ 3.71	$ (10.83)	$ 5.40
Diluted (in usd per share)	$ (1.00)	$ 3.69	$ (10.83)	$ 5.38
Weighted-average common shares
Basic (in shares)	351.5	350.4	351.1	350.1
Diluted (in shares)	351.5	352.3	351.1	351.4
Product sales
Revenues
Revenues	$ 2,108	$ 2,186	$ 6,173	$ 6,462
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	573	650	1,717	1,869
Other revenues
Revenues
Revenues	28	33	86	99
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	$ 9	$ 9	$ 32	$ 32